Robert F. Kennedy Jr. has successfully pressured the U.S. Food and Drug Administration (FDA) to revisit its 2023 ban on 12 unproven peptides, despite the absence of new safety or efficacy data. The move comes as part of Kennedy’s broader campaign to challenge regulatory decisions on therapeutic compounds.
The peptides in question were banned due to insufficient evidence supporting their medical benefits and potential safety risks. FDA officials, speaking on condition of anonymity, confirmed the reevaluation but emphasized that the process does not imply a policy reversal. “This is a standard regulatory review prompted by new petitions,” one official stated.
Medical experts remain skeptical. Dr. Sarah Chen, a pharmacologist at Johns Hopkins University, noted: “There’s no peer-reviewed research since the ban that changes the risk-benefit calculus. This appears to be political pressure rather than science-driven policy.”
The outcome could set a precedent for how the FDA handles similar challenges to its regulatory authority. Analysts suggest the decision may influence upcoming legislation on accelerated approval pathways for novel therapies.